Complete Response to Pembrolizumab After Progression on Avelumab Maintenance in Metastatic Urothelial Carcinoma
IJU Case Reports · 2026-03 · 9 (2)
DOI: 10.1002/iju5.70160 ↗Kurz gefasst
Fachartikel in der Zeitschrift IJU Case Reports, online erschienen am 08.03.2026. Verfasst von Fumihiro Ito und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Gifu Prefectural Tajimi Hospital Tajimi Japan. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Avelumab maintenance after response to platinum chemotherapy improves outcomes in metastatic urothelial carcinoma. Progression during maintenance presents a therapeutic dilemma. Case Presentation A 72‐year‐old man underwent radical cystectomy and left nephroureterectomy for high‐grade urothelial carcinoma. Two and a half years later, a solitary pelvic nodal recurrence achieved complete response to gemcitabine–cisplatin, after which avelumab maintenance was started. After 16 cycles, the same node regrew, indicating progression. Pembrolizumab was initiated and induced a second complete response after four cycles. He remains recurrence‐free for three years without immune‐related adverse events.
Conclusion
Durable remission with pembrolizumab following progression on avelumab suggests that switching from PD‐L1 to PD‐1 blockade can overcome resistance in selected patients; prospective studies and biomarker strategies, including PD‐L2 assessment, are warranted and may guide individualized rechallenge strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology Gifu Prefectural Tajimi Hospital Tajimi Japan.
ORCID-Profile: Fumihiro Ito
Zitieren
APA
Ito, F., Kobayashi, K., Hayashi, G., Kamijo, S., & Fujita, T. (2026). Complete Response to Pembrolizumab After Progression on Avelumab Maintenance in Metastatic Urothelial Carcinoma. IJU Case Reports, 9(2). https://doi.org/10.1002/iju5.70160
Vancouver
Ito F, Kobayashi K, Hayashi G, Kamijo S, Fujita T. Complete Response to Pembrolizumab After Progression on Avelumab Maintenance in Metastatic Urothelial Carcinoma. IJU Case Reports. 2026;9(2). doi:10.1002/iju5.70160
BibTeX
@article{Ito2026,
author = {Ito, Fumihiro and Kobayashi, Koki and Hayashi, Gaku and Kamijo, Shunsuke and Fujita, Takashi},
title = {Complete Response to Pembrolizumab After Progression on Avelumab Maintenance in Metastatic Urothelial Carcinoma},
journal = {IJU Case Reports},
year = {2026},
volume = {9},
number = {2},
doi = {10.1002/iju5.70160}
}
EUVIMED